0.157 USD
-0.01 (-5.42%)
0.1507 USD
-0.01 (-4.01%)
GLYC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. The financial health of GLYC is average, but there are quite some concerns on its profitability. GLYC does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year GLYC has reported negative net income.
- In the past year GLYC has reported a negative cash flow from operations.
- GLYC had negative earnings in each of the past 5 years.
- In the past 5 years GLYC always reported negative operating cash flow.
1.2 Ratios
- GLYC has a worse Return On Assets (-341.52%) than 94.25% of its industry peers.
- Looking at the Return On Equity, with a value of -712.87%, GLYC is doing worse than 81.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -341.52% | ||
| ROE | -712.87% | ||
| ROIC | N/A |
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for GLYC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- GLYC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- GLYC has about the same amout of shares outstanding than it did 1 year ago.
- Compared to 5 years ago, GLYC has more shares outstanding
- GLYC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- GLYC has an Altman-Z score of -70.45. This is a bad value and indicates that GLYC is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of GLYC (-70.45) is worse than 96.05% of its industry peers.
- There is no outstanding debt for GLYC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -70.45 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
- GLYC has a Current Ratio of 1.92. This is a normal value and indicates that GLYC is financially healthy and should not expect problems in meeting its short term obligations.
- GLYC has a Current ratio of 1.92. This is in the lower half of the industry: GLYC underperforms 77.38% of its industry peers.
- GLYC has a Quick Ratio of 1.92. This is a normal value and indicates that GLYC is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.92, GLYC is not doing good in the industry: 76.12% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.92 |
3. Growth
3.1 Past
- GLYC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.09%, which is quite impressive.
- Looking at the last year, GLYC shows a very negative growth in Revenue. The Revenue has decreased by -87.50% in the last year.
- The Revenue for GLYC have been decreasing by -90.05% on average. This is quite bad
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.47%
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 14.05% on average over the next years. This is quite good.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.84%
EPS Next 2Y-87.54%
EPS Next 3Y-74.09%
EPS Next 5Y14.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- GLYC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLYC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- GLYC's earnings are expected to decrease with -74.09% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-87.54%
EPS Next 3Y-74.09%
5. Dividend
5.1 Amount
- No dividends for GLYC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GLYCOMIMETICS INC / GLYC FAQ
Can you provide the ChartMill fundamental rating for GLYCOMIMETICS INC?
ChartMill assigns a fundamental rating of 2 / 10 to GLYC.
What is the valuation status for GLYC stock?
ChartMill assigns a valuation rating of 1 / 10 to GLYCOMIMETICS INC (GLYC). This can be considered as Overvalued.
How profitable is GLYCOMIMETICS INC (GLYC) stock?
GLYCOMIMETICS INC (GLYC) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for GLYC stock?
The Earnings per Share (EPS) of GLYCOMIMETICS INC (GLYC) is expected to decline by -6.84% in the next year.